Riassunto
Il sospetto di recidiva dopo terapia per adenocarcinoma della prostata è dato da un aumento dei livelli del PSA, che sono differenti a seconda del trattamento. Si parla di ricorrenza di malattia dopo prostatectomia radicale retropubica (RRP) per valori di PSA > 0,2 ng/mL in due dosaggi consecutivi; dopo radioterapia (RT) per almeno due aumenti consecutivi del PSA rispetto al suo valore al nadir raggiunto dopo radioterapia [1].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Bibliografia
Amling CL, Bergstralh EJ, Zincke H et al (2001) Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 65(4):1146–1151
Grossfeld GD, Stier M, Carroll PR et al (1998) Use of second treatment following definitive local therapy for prostate cancer: data from the caPSURE database. J Urol 160(4):1398–1404
Zerbib M, Zelefsky M, Higano CS, Carroll PR (2008) Conventional treatments of localized prostate cancer. Urology 72 (Suppl 6A):S25–S35
Walz J, Chun F, Karakiewicz P et al (2009) Nomogram predicting the probability of early recurrence after radical prostatectomy for prostate cancer. J Urol 181:601–608
Dillioglugil O, Leibman BD, Kattan MW et al (1997) Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer. Urology 50:93–99
Pound CR, Partin AW, Eisenberger MA, Walsh PC et al (1999) Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281:1591–1597
Freedland SJ, Humphreys EB, Mangold LA et al (2006) Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality. J Urol; 176:1404–1408
Lu-Yao GL, Potosky AL, Albertsen PC et al (1996) Follow-up prostate cancer treatments after radical prostatectomy: a population-based study. J Natl Cancer Inst 88(3–4):166–173
Zerbib M, Zelefsky MJ, Higano CS, Carroll PR (2008) Conventional treatments of localized prostate cancer. Urology 72(Suppl 6):S25–35
Kato T, Obata Y, Kadoya N, Fuwa N (2009) A comparison of prone three-dimensional conformal radiotherapy with supine intensity-modulated radiotherapy for prostate cancer: which technique is more effective for rectal sparing? Br J Radiol. 82(980):654–661
Marberger M, Carroll PR, Zelefsky MJ et al (2008) New treatments for localized prostate cancer. Urology 72(Suppl 6): S36–S43
Stock RG, Klein TJ, Cesaretti JA, Stone NN (2009) Prognostic significance of 5-year PSA value for predicting prostate cancer recurrence after brachytherapy alone and combined with hormonal therapy and/or external beam radiotherapy. Int J Radiat Oncol Biol Phys 74(3):753–758
Kaouk JH, Hafron J, Goel R et al (2008) Robotic salvage retropubic prostatectomy after radiation/brachytherapy: initial results. BJU Int 102(1):93–96
Zagars GK, Pollack A, von Eschenbach AC (1995) Prostate cancer and radiation therapy: the message conveyed by serum prostate-specific antigen. Int J Radiat Oncol Biol Phys 33(1):23–35
Makarov DV, Trock BJ, Humphreys EB et al (2007) Update nomogram to predict pathologic stage of cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005. Urology 69(6):1095–1101
Lange PH, Ercole CJ, Lightner DJ et al (1989) The value of serum prostate specific antigen determinations before and after radical prostatectomy. J Urol 141(4):873–879
Trapasso JG, deKernion JB, Smith RB, Dorey F (1994) The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy. J Urol 152(5 Pt 2):1821–1825
Yossepowitch O, Bjartell A, Eastham JA et al (2008) Positive surgical margins in radical prostatectomy: outlining the problem and its long-term consequences. Eur Urol [Oct 1 Epub ahead of print]
Pettus JA, Weight CJ, Thompson CJ et al (2004) Biochemical failure in men following radical retropubic prostatectomy: impact of surgical margin status and location. J Urol. 172(1):129–132
Palisaar RJ, Noldus J, Graefen M et al (2005) Influence of nerve sparing procedure during radical prostatectomy on margin status and biochemical failure. Eur Urol 47(2):176–184
Terakawa T, Miyake H, Tanaka K et al (2008) Surgical margin status of open versus laparoscopic radical prostatectomy specimens. Int J Urol 15(8):704–7; discussion 708
Dinniwell R, Chan P, Czarnota G et al (2009) Pelvic lymph node topography for radiotherapy treatment planning from ferumoxtran-10 contrast-enhanced magnetic resonance imaging. Int J Radiat Oncol Biol Phys 74(3):844–851
Beissert M, Lorenz R, Gerharz EW (2008) Rational imaging in locally advanced prostate cancer. Urologe A 47(11): 1405–1416
Picchio M, Crivellaro C, Giovacchini G et al (2009) PETCT for treatment planning in prostate cancer. Q J Nucl Med Mol Imaging 53(2):245–268
Saleem MD, Sanders H, Abu El Naser M, El-Galley R (1998) Factors predicting cancer detection in biopsy of the prostatic fossa after radical prostatectomy. Urology; 51(2): 283–286
Stephenson AJ, Scardino PT, Kattan MW et al (2007) Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol; 25(15):2035–2041
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer-Verlag Italia
About this chapter
Cite this chapter
Gentilucci, A., Salciccia, S., Buscarini, M. (2010). La prostata operata: il sospetto clinico di recidiva. In: Passariello, R., Panebianco, V., Di Silverio, F., Sciarra, A. (eds) Imaging RM della prostata. Springer, Milano. https://doi.org/10.1007/978-88-470-1516-6_18
Download citation
DOI: https://doi.org/10.1007/978-88-470-1516-6_18
Publisher Name: Springer, Milano
Print ISBN: 978-88-470-1515-9
Online ISBN: 978-88-470-1516-6
eBook Packages: MedicineMedicine (R0)